Last reviewed · How we verify
REPAGLINIDE
REPAGLINIDE is a Glinide [EPC] drug. It is currently FDA-approved (first approved 1997).
Repaglinide is a small molecule that acts as a blocker of the Sulfonylurea receptor 1, Kir6.2. It is classified as a BLOCKER drug class.
At a glance
| Generic name | REPAGLINIDE |
|---|---|
| Drug class | Glinide [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
- Upper Respiratory Infection
- Headache
- Sinusitis
- Arthralgia
- Nausea
- Diarrhea
- Back Pain
- Rhinitis
- Constipation
- Vomiting
- Paresthesia
- Chest pain
Key clinical trials
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (PHASE1)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (PHASE1, PHASE2)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REPAGLINIDE CI brief — competitive landscape report
- REPAGLINIDE updates RSS · CI watch RSS
Frequently asked questions about REPAGLINIDE
What is REPAGLINIDE?
REPAGLINIDE is a Glinide [EPC] drug.
What drug class is REPAGLINIDE in?
REPAGLINIDE belongs to the Glinide [EPC] class. See all Glinide [EPC] drugs at /class/glinide-epc.
When was REPAGLINIDE approved?
REPAGLINIDE was first approved on 1997.
What development phase is REPAGLINIDE in?
REPAGLINIDE is FDA-approved (marketed).
What are the side effects of REPAGLINIDE?
Common side effects of REPAGLINIDE include Upper Respiratory Infection, Headache, Sinusitis, Arthralgia, Nausea, Diarrhea.
Related
- Drug class: All Glinide [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing